Table 3.
Risk Factor Model To Predict Variables Associated With Receiving a Targeted Ceftazidime-Avibactam Versus Colistin-based Regimen
| Variable | Relative Risk of Receiving Ceftazidime-Avibactam Versus Colistina (95% CI) |
|---|---|
| Age (years) | 1.01 (.96–1.06) |
| Sex (male) | 1.05 (.96–1.15) |
| APR-ARG SOIb | |
| Moderate | 2.07 (1.12–3.81) |
| Major | 2.00 (1.09–3.66) |
| Extreme | 1.75 (.95–3.22) |
| Septic shock | 1.05 (.95–1.15) |
| Mechanical ventilation | 0.80 (.70–.90) |
| Vasopressor administration | 1.11 (1.00–1.23) |
| Comorbid conditionsc | |
| Elixhauser comorbidity index | 0.96 (.94–.98) |
| Congestive heart failure | 1.00 (.90–1.11) |
| Chronic kidney disease | 2.02 (1.82–2.25) |
| Diabetes | 1.14 (1.04–1.26) |
| Transplant | 0.72 (.59–.89) |
| Dialysis | 0.71 (.61–.83) |
| Metastatic cancer | 1.18 (.96–1.47) |
| Neutropenia | 1.16 (.94–1.43) |
| Tracheostomy | 0.67 (.58–.78) |
| Presumed site of infectiond | |
| Abdominal | 1.68 (1.51–1.87) |
| Bacteremia | 1.01 (.88–1.17) |
| Central nervous system | 1.65 (.81–3.37) |
| Central venous catheter | 1.44 (1.27–1.64) |
| Respiratory | 0.94 (.85–1.04) |
| Skin/soft tissue | 1.50 (1.35–1.68) |
| Urine | 0.93 (.84–1.04) |
| Unknown source | 0.4 (.34–.47) |
| Hospital regione | |
| Northeast | 1.63 (1.46–1.83) |
| South | 0.90 (.78–1.04) |
| West | 1.10 (.94–1.29) |
| Hospital teaching status | 0.93 (.70–1.25) |
| Hospital bed capacityf | |
| 250–499 | 0.92 (.65–1.31) |
| 500–749 | 1.27 (.90–1.80) |
| ≥750 | 1.21 (.85–1.71) |
| Admission quarterg | 1.08 (1.06–1.10) |
Abbreviations: APR-DRG, All Patient Refined Diagnosis Related Group; CI, confidence interval; IQR, interquartile range; SOI, severity of illness.
aRelative risk >1 favors ceftazidime-avibactam and <1 favors colistin.
bAPR-DRG SOI compared with minor.
cComorbid conditions reported on admission.
dSite of infection not mutually exclusive.
eCompared with Midwest.
fBed capacity compared with <250.
gReported as a continuous variable.